Tandem's Elizabeth Gasser discusses her plans for patch pumps and partnership with Abbott
Tandem Diabetes Care Advances Diabetes Technology with New Integrations and Developments
Tandem Diabetes Care, a leading player in the diabetes technology sector, is making significant strides in enhancing its offerings. The company is currently integrating Abbott's latest Continuous Glucose Monitoring (CGM) sensor, the FreeStyle Libre 3 Plus, with its t:slim X2 insulin pump, marking a significant step in integrating CGM technology with insulin delivery systems.
This integration, now officially launched in the United States as of July 2025, enables users of Tandem's insulin pumps to receive real-time glucose data from the FreeStyle Libre 3 Plus sensor, thereby enhancing automated insulin delivery capabilities.
Regarding Tandem's planned patch pumps, namely Mobi and Sigi, while these are part of Tandem's strategic product portfolio, specific timelines for their commercial release or widespread adoption have not been detailed in currently available sources. Mobi, described as an automated insulin delivery system, is designed to challenge people's assumptions about what it means to be tubeless. Sigi, on the other hand, is a patch pump designed specifically for tubeless wear and will come after Mobi.
Tandem is also actively working on a research collaboration with the University of Virginia Center for Diabetes Technology, aimed at developing fully automated closed-loop insulin delivery systems. This suggests ongoing development and potential future innovations leveraging integrated CGM and insulin pump technologies.
Abbott is also expanding integrations across several automated insulin delivery players, including Tandem Diabetes Care, to enhance interoperability and user experience for diabetes management. Abbott’s FreeStyle Libre CGM sales are growing strongly, and ongoing improvements in sensor technology are expected to accelerate adoption and integration with insulin delivery systems.
As Tandem Diabetes Care continues to innovate and improve its diabetes technology offerings, the company recognizes the need for investing with intensity and pace to plug these ecosystems together. The company also acknowledges growing competition in the diabetes tech sector and is keeping up with the developments, including new patch pumps and glucose sensors.
No detailed or updated timelines beyond 2025 for Mobi or Sigi patch pumps were found, and public statements indicate that such new devices generally will not be available before 2027. However, Tandem Diabetes Care is also planning to connect its insulin pumps with Abbott's planned glucose-ketone sensor, further enhancing its diabetes management offerings.
In summary, as of July 2025, Tandem Diabetes Care is actively integrating Abbott’s latest CGM sensor for superior automated insulin delivery but is still developing next-generation patch pump devices with no immediate commercial release date disclosed. The company's goal is to reach as many people with diabetes as possible, and it is investing heavily in research and development to achieve this goal.
- Tandem Diabetes Care is partnering with the University of Virginia Center for Diabetes Technology for research aimed at developing fully automated closed-loop insulin delivery systems, displaying ongoing commitment to advancements in medtech.
- As part of their strategic product portfolio, Tandem Diabetes Care is developing two patch pumps, Mobi and Sigi, both designed to enhance health-and-wellness for diabetes patients.
- The company's integration of Abbott's FreeStyle Libre 3 Plus CGM sensor with its t:slim X2 insulin pump represents a milestone for AI and science in medical-conditions management, providing real-time glucose analytics for users.
- The ongoing news in the medtech industry includes Abbott expanding integrations with various automated insulin delivery providers to improve interoperability and user experience.
- In their quest to remain competitive in the medical-conditions sector, Tandem Diabetes Care is planning to connect their insulin pumps with Abbott's future glucose-ketone sensor, bolstering their offerings in the technology arena.
